| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.6 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |